Full Text View
Tabular View
No Study Results Posted
Related Studies
Thalidomide Plus Interferon Alfa in Treating Patients With Progressive Liver Cancer That Cannot be Surgically Removed
This study has been completed.
Study NCT00006006   Information provided by National Cancer Institute (NCI)

First Received on July 5, 2000.   Last Updated on February 8, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Liver Cancer
Additional conditions recognized in this trial
Disease Progression
Liver Neoplasms
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Disease Attributes
Liver Diseases
Neoplasms
Neoplasms by Site
Pathologic Processes
Interventions listed in this trial
recombinant interferon alfa
thalidomide
Additional drug interventions recognized in this trial
Interferon Alfa-2a
Interferon-alpha
Interferons
More general drug interventions related to this trial
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Anti-Bacterial Agents
Anti-Infective Agents
Antineoplastic Agents
Antiviral Agents
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Leprostatic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services